Navigation Links
VolitionRX to Begin Prospective Clinical Trial in Colon Cancer
Date:8/21/2012

SINGAPORE, Aug. 21, 2012 /PRNewswire/ -- VolitionRX Limited, a life sciences company focused on developing blood-based diagnostic tests, announces that its subsidiary Belgian Volition has signed an agreement with the Biobank of CHU UCL Mont-Godinne, an academic hospital in Yvoir, Belgium. This is the fourth large-scale external clinical trial for VolitionRX. The trial will begin in early September, and is scheduled for completion next year. The trial will be a prospective longitudinal study including approximately 250 patients as they progress through diagnosis and treatment. The project aims to develop and clinically evaluate non-invasive blood tests for early detection and prognosis of colorectal cancer.

Patient recruitment and sampling will take place in the Gastro-Enterology and Oncology Departments of the CHU UCL Mont-Godinne Hospital. Patients with a potential digestive pathology (including a mixture of suspected colorectal cancer, polyp, inflammatory bowel disease ("IBD"), Crohn's disease and colitis) will be given a blood test alongside a colonoscopy. Samples will be taken from the following cohorts:

  • Patients with positive colonoscopy for IBD or polyp: initial sample plus a follow-up blood test
  • Patients with positive colonoscopy for cancer, and treated as follows:
    • Surgery only: initial samples followed by a further blood sample approximately one month after surgery;
    • Surgery followed by chemotherapy: initial sample followed by further samples pre and post chemotherapy treatment rounds;
    • Chemotherapy followed by surgery: initial sample followed by further samples pre and post chemotherapy treatment rounds and surgery;
  • Patients with negative colonoscopy for IBD, polyp or cancer will form an age-matched healthy control cohort.

Belgian Volition will analyze the samples using its NuQ™ kits, at its laboratory in Namur, Belgium.

Jake Micallef, Chief Scientific Officer of Belgian Volition says: "This clinical trial will be our first validation study of our NuQ blood-based tests specifically on a single cancer – colorectal cancer, which is one of the most prevalent cancers, both in Belgium and worldwide. Our aim is to distinguish between patients with cancer and those with digestive conditions presenting with similar symptoms."

Cameron Reynolds, President & CEO of VolitionRX says: "We're extremely grateful to the Walloon Region of Belgium for their support and funding, which will assist us in carrying out this study into colorectal cancer. We are pleased to be working with another first-class hospital to validate our tests – ensuring that sample collection takes place exactly as it will would be when clinically available."

About VolitionRX
VolitionRX is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats.

VolitionRX's development activities are currently centered in Belgium and will be augmented by commercialization work in Singapore with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.

You can find more information about VolitionRX at our website at www.volitionrx.com, on Twitter at www.twitter.com/VolitionRX, LinkedIn at www.linkedin.com/company/1364072?trk=tyah or Facebook at www.facebook.com/volitionrx.

Forward-Looking Statements: Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE VolitionRX Limited
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SuccessEHS "Forward Together" Customer Conference Begins
2. Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial
3. Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease
4. Nouveau Life Pharmaceuticals (NOUV) to Begin Sales of Azul Instant™
5. Divine Skin To Begin Manufacturing Its OTC Pain Reliever
6. Siteman Cancer Center at Barnes-Jewish and Washington University Begins Imaging with First ViewRay System
7. K-V Pharmaceutical Class A and Class B Common Stock Begin Trading on the OTC Markets
8. Countdown Begins For AdvaMed 2012: The Medtech Conference
9. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
10. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
11. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017  Novartis announced today ... has accepted the company,s Biologics License Application (BLA) ... an investigational chimeric antigen receptor T cell (CAR-T) ... young adult patients with B-cell acute lymphoblastic leukemia ... Novartis for a CAR-T. The priority review designation ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "South ... & Forecast" report to their offering. ... The South Korean Proton Therapy Market is expected to ... Untapped Proton Therapy Market for South Korea was ... Proton Therapy plays an important role in delivering comprehensive cancer care to ...
(Date:3/29/2017)... 29, 2017  Zynex (OTCQB: ZYXI), an innovative medical technology ... medical devices for pain management, stroke rehabilitation, cardiac monitoring ... the Company,s 2016 full-year investor webcast on Monday, April 3, ... The Company expects to file its 2016 full year ... ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 2017 , ... Patients interested in receiving quick and effective ... Cameron, with or without a referral. The FASTBRACES system is valued for its ... patient’s case, treatment with the FASTBRACES system could be completed in 120 days ...
(Date:3/29/2017)... ANN ARBOR, Mich. (PRWEB) , ... ... ... Global Retailer and Manufacturer Alliance (GRMA) is growing as it continues developing ... the dietary supplement industry. The organization, which plans to publish the first ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... oral braces. "The rubber bands used in conjunction with my braces always rubbed ... to design a way to prevent this problem." The O.B.S. was the result ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly ... assembly protocols involve many repetitive steps and often scientists require many different versions ... high-throughput needed, and results in a lower error rate and cost saving for ...
Breaking Medicine News(10 mins):